Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 8/20 | 1.00 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.52 |
| ▸ | CDK14 | O94921 | 2/20 | 0.49 |
| ▸ | CCNY | Q8ND76 | 2/20 | 0.49 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20206219 | 0.97 | IRAK1 (1.00) | IRAK1MAP3K19IRAK4CDK14CCNY | |
| SCHEMBL20206093 | 0.94 | IRAK1 (1.00) | IRAK1MAP3K19IRAK4CDK14CCNY | |
| SCHEMBL20190995 | 0.92 | IRAK1 (1.00) | IRAK1MAP3K19IRAK4CDK14CCNY | |
| SCHEMBL20206248 | 0.89 | IRAK1 (0.80) | IRAK1MAP3K19IRAK4CDK14CCNY | |
| SCHEMBL20190992 | 0.89 | IRAK1 (0.86) | IRAK1MAP3K19IRAK4CDK14CCNY | |
| SCHEMBL24021411 | 0.88 | IRAK1 (0.78) | IRAK1MAP3K19IRAK4BCAT2 | |
| SCHEMBL23683307 | 0.85 | IRAK1 (0.81) | IRAK1MAP3K19IRAK4CDK14CCNY | |
| SCHEMBL21345573 | 0.85 | IRAK1 (1.00) | IRAK1MAP3K19CDK14CCNYBCAT2 | |
| SCHEMBL20206252 | 0.84 | IRAK1 (1.00) | IRAK1MAP3K19IRAK4BCAT2MAPK10 | |
| SCHEMBL24021469 | 0.84 | IRAK1 (0.77) | IRAK1MAP3K19IRAK4BCAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542251-B2 | IRAK degraders and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3544970-B1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20210230144-A1 | IRAK DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018098367-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885IRAK4 2/4885 |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885IRAK4 2/4885 |
| US-11542251-B2 | IRAK degraders and uses thereof | IRAK2, IRAK1, IRAK4 | IRAK1 2/4885MAP3K19 121/4885IRAK4 3/4885 |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885IRAK4 2/4885 |
| US-20210230144-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK1, IRAK4 | IRAK1 2/4885MAP3K19 121/4885IRAK4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.